Back to Search Start Over

Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19

Authors :
Isa Khaheshi
Mohammad Amin Shahrbaf
Mohammadreza Tabary
Source :
Cardiovascular & Hematological Disorders-Drug Targets. 21:88-90
Publication Year :
2021
Publisher :
Bentham Science Publishers Ltd., 2021.

Abstract

After the outbreak of COVID-19, many novel drugs have been introduced to improve patients’ conditions. Remdesivir and Favipiravir are among the most common drugs used against SARS-CoV-2. Although promising, cardiovascular side effects of these drugs should be considered by physicians and nurses. In this study, we searched databases for assessing the cardiovascular side effects of Remdesivir and Favipiravir. It seems that despite the beneficial effects of these drugs, due to the cardiovascular complications of COVID-19 and cardiovascular side effects of these drugs, which can overlap with each other, the use of these drugs can be a challenging issue in the cardiovascular practice.

Details

ISSN :
1871529X
Volume :
21
Database :
OpenAIRE
Journal :
Cardiovascular & Hematological Disorders-Drug Targets
Accession number :
edsair.doi.dedup.....4d289af6ebfc7fb0be28a27facdbbf84
Full Text :
https://doi.org/10.2174/1871529x21666210812103535